. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18;71(21):1702-8. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. It would be appropriate to try doing a trial of IGF-1 BP3
    (Iplex) at a
    higher dose. As ALS patients, many of us do not have two years
    to waste on
    stupidity. I used Iplex briefly before the lawsuit rendered it
    unavailable. My "anecdotal" evidence supported slight improvement
    in a short period of
    time. Worth a shot when it comes to people waiting to die,
    isn't it?

    View all comments by Deborah Gattoni

Make a Comment

To make a comment you must login or register.